HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature

Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathiot, Laurent, Herbreteau, Guillaume, Robin, Siméon, Fenat, Charlotte, Bennouna, Jaafar, Blanquart, Christophe, Denis, Marc, Pons-Tostivint, Elvire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139372/
https://www.ncbi.nlm.nih.gov/pubmed/35621690
http://dx.doi.org/10.3390/curroncol29050300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139372/
https://www.ncbi.nlm.nih.gov/pubmed/35621690
http://dx.doi.org/10.3390/curroncol29050300

Ejemplares similares